— Conference Call Scheduled for Tuesday, May 5, 2020 at 4:30 p.m. ET — ROCKVILLE, Md., April 28, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the Company […]
ROCKVILLE, Md., Feb. 7, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that the NYSE American LLC (the “Exchange”) has accepted the Company’s plan of compliance (the “Plan”) for
Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American Read More »
ROCKVILLE, Md., Feb. 4, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, announced today that Steven A. Shallcross, Chief Executive and Financial Officer, is scheduled to present at the BIO CEO &
Synthetic Biologics to Present at the 2020 BIO CEO & Investor Conference Read More »
ROCKVILLE, Md., Jan. 7, 2020 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced the receipt of official meeting minutes from the U.S. Food and Drug Administration (FDA) following a Type C
ROCKVILLE, Md., Nov. 27, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it has received written communication from NYSE American LLC (the “Exchange”), the Company’s current listing exchange, stating
Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan Read More »
— Issuance of New Patent and Allowance of Patent Application Diversifies SYN-010 Protection in US — ROCKVILLE, Md., Sept. 26, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today that the U.S. Patent and Trademark Office
ROCKVILLE, Md., July 1, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today receipt, on June 28, 2019, of notification from the NYSE American LLC (the “Exchange”) that the Company has regained compliance with Part 10,
Synthetic Biologics Regains Compliance with NYSE American Continued Listing Standards Read More »
— Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 — — Conference Call Wednesday, February 27, 2019, at 4:30 p.m. (EST) — ROCKVILLE, Md., Feb. 27, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a clinical-stage company developing therapeutics that preserve
Synthetic Biologics Reports 2018 Year End Operational Highlights and Financial Results Read More »
Clinical Study of SYN-010, for the Treatment of IBS-C ROCKVILLE, Md., Jan. 3, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that the first two patients have been enrolled in SYN-010’s Phase 2b investigator-sponsored clinical
— Single Phase 3 Clinical Trial May be Sufficient for Approval for Prevention of Antibiotic-Mediated Clostridium difficile Infection (CDI) — — SYN-004 (ribaxamase) is in Development as Potentially the First Intervention Designed to Specifically Prevent Antibiotic Damage to the Microbiome — ROCKVILLE, Md., Nov. 21, 2018 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage
